HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the... |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
CAMPTOSAR® (irinotecan HCl)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
CAMPTOSAR® Quick Finder
WARNING: DIARRHEA and MYELOSUPPRESSION
- Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late...
1 INDICATIONS AND USAGE
- CAMPTOSAR is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.
- ...
2 DOSAGE AND ADMINISTRATION
2.1 Colorectal Cancer Combination Regimens 1 and 2
Administer CAMPTOSAR as a 90-minute intravenous infusion followed by LV and 5-FU. The...
3 DOSAGE FORMS AND STRENGTHS
Injection: 40 mg/2 mL (20 mg/mL), 100 mg/5 mL (20 mg/mL), and 300 mg/15 mL (20 mg/mL) sterile, pale yellow, clear, aqueous solution in a single-dose vial.
4 CONTRAINDICATIONS
- CAMPTOSAR Injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients.
5 WARNINGS AND PRECAUTIONS
5.1 Diarrhea and Cholinergic Reactions
Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) is usually transient and...
6 ADVERSE REACTIONS
6.1 Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the...
7 DRUG INTERACTIONS
7.1 5-Fluorouracil (5-FU) and Leucovorin (LV)
In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26...
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on findings from...
10 OVERDOSAGE
In U.S. phase 1 trials, single doses of up to 345 mg/m2 of irinotecan were administered to patients with various cancers. Single doses of up to 750 mg/m2 of...
11 DESCRIPTION
CAMPTOSAR Injection (irinotecan hydrochloride injection) is an antineoplastic agent of the topoisomerase I inhibitor class.
CAMPTOSAR is supplied as a sterile, pale yellow, clear, aqueous solution. Each...
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I,...
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term carcinogenicity studies with irinotecan were not conducted. Rats were,...
14 CLINICAL STUDIES
Irinotecan has been studied in clinical trials in combination with 5-fluorouracil (5-FU) and leucovorin (LV) and as a single agent [see Dosage and Administration (2)...
15 REFERENCES
- "OSHA Hazardous Drugs." OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
16 HOW SUPPLIED/STORAGE AND HANDLING
CAMPTOSAR (irinotecan hydrochloride) Injection is available as a sterile, pale yellow, clear, aqueous solution in a vial packaged within a carton in the following packaging configurations...
17 PATIENT COUNSELING INFORMATION
- Patients and caregivers should be informed of gastrointestinal complications, such as nausea, vomiting, abdominal cramping, and diarrhea. Patients should have loperamide readily...
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.